4.4 Article

Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia

期刊

INFECTION AND IMMUNITY
卷 70, 期 3, 页码 1069-1074

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.70.3.1069-1074.2002

关键词

-

资金

  1. NHLBI NIH HHS [HL55002, R01 HL055002] Funding Source: Medline
  2. NIAID NIH HHS [AI23302, R01 AI023302, AI45479] Funding Source: Medline
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055002] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023302, R21AI045479] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Passive antibody immunoprophylaxis is one method used to protect patients against infection if they are unable to mount an adequate active immune response. Topical application of antibody may be effective against infections at mucosal sites. Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protection against an airborne challenge with P. carinii by intranasal administration of antibody. Immunoglobulin M (IgM) monoclonal antibodies to an epitope shared by mouse and human P. carinii organisms reduced organism numbers by more than 99% under the conditions described. An IgG1 switch variant of one of the IgM monoclonal antibodies was also protective. These experiments provide a model for exploring the utility of this approach in protecting at-risk patients from infection with A carinii.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据